A Phase I Trial of First-in-Human Alpha-Emitter Astatine-211-Labeled Anti-CD45 Antibody (211At-BC8-B10) in Combination with Fludarabine and TBI As Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS): Preliminary Results of Dose Escalation

Brenda M. Sandmaier, D. Scott Wilbur, Donald K. Hamlin, Phuong Vo, Roger Wong, Kelsey Baker, Robyn L. Haaf, M Bouvier, Manuela C. Matesan, Yawen Li, Johnnie J. Orozco, Margaret E. Nartea, Erlinda B. Santos, Eric Dorman, Hubert Vesselle, David H. Lewis, Sanaz Behnia, Damian J. Green, Robert Emery, Joseph G. Rajendran, Ted Gooley, Rainer Storb